HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Protein degraders gain speed as Arvinas scores landmark approval

Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.

By PharmaVoice · May 4, 2026 · via PharmaVoice
Protein degraders gain speed as Arvinas scores landmark approval

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
pipelineformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
PipelineFiercePharma ↗
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
May 25, 2026
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
PipelineFiercePharma ↗
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
May 24, 2026
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
PipelineFiercePharma ↗
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …
May 23, 2026